India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients MUMBAI, India and ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

Leqselvi (deuruxolitinib) is now available for the treatment of adults with severe alopecia areata.

India business is expected to grow 10 to 12 percent YoY, driven by volume gains, in-licensing deals, and new launches.

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

As part of the agreement, Incyte has granted Sun Pharma a limited, non-exclusive license to US Patent Nos. 9,662,335 and other related patents.

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. Sun’s Leqselvi is now available for prescription to eligible patients with ...

LEQSELVI demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24.

LEQSELVI (deuruxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2 approved for the treatment of adults with severe alopecia areata.